Springer Medicine
@springermedicine.com
Trustworthy, tailored, cutting-edge content for medical professionals who want to deliver the best possible care. Learn more here: springermedicine.com
Join leading expert Dr. Alice Cheng for practical insights into the safety, efficacy, and implementation of once-weekly #insulin therapy for #T2D and how to optimize patient care.
Register for free here 👉 buff.ly/p6VCKir
#Diabetes #MedEd
Register for free here 👉 buff.ly/p6VCKir
#Diabetes #MedEd
February 5, 2026 at 4:16 PM
Join leading expert Dr. Alice Cheng for practical insights into the safety, efficacy, and implementation of once-weekly #insulin therapy for #T2D and how to optimize patient care.
Register for free here 👉 buff.ly/p6VCKir
#Diabetes #MedEd
Register for free here 👉 buff.ly/p6VCKir
#Diabetes #MedEd
Enhance your knowledge, skills and practice in molecular testing, emerging therapies, and targeted treatments in R/R #AML with this vodcast series hosted by Prof. Amer Zeidan.
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemSky #MedEd
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemSky #MedEd
January 14, 2026 at 9:02 AM
Enhance your knowledge, skills and practice in molecular testing, emerging therapies, and targeted treatments in R/R #AML with this vodcast series hosted by Prof. Amer Zeidan.
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemSky #MedEd
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemSky #MedEd
How can you optimize your patient care amidst a new era of #insulin therapy?
Join our expert-led webinar to find out and have the opportunity to ask questions to fine-tune your clinical practice.
Register for free 👉 buff.ly/SKALXgN
#Diabetes #T2D
Join our expert-led webinar to find out and have the opportunity to ask questions to fine-tune your clinical practice.
Register for free 👉 buff.ly/SKALXgN
#Diabetes #T2D
January 9, 2026 at 3:49 PM
How can you optimize your patient care amidst a new era of #insulin therapy?
Join our expert-led webinar to find out and have the opportunity to ask questions to fine-tune your clinical practice.
Register for free 👉 buff.ly/SKALXgN
#Diabetes #T2D
Join our expert-led webinar to find out and have the opportunity to ask questions to fine-tune your clinical practice.
Register for free 👉 buff.ly/SKALXgN
#Diabetes #T2D
Prof. Amer Zeidan and guest experts dive into the latest innovations in molecular testing, emerging therapies & targeted treatments in R/R acute myeloid leukemia #AML in this vodcast series.
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemOnc
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemOnc
December 23, 2025 at 11:54 AM
Prof. Amer Zeidan and guest experts dive into the latest innovations in molecular testing, emerging therapies & targeted treatments in R/R acute myeloid leukemia #AML in this vodcast series.
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemOnc
All episodes available now 👉 buff.ly/ro4GLtX
#OncSky #HaemOnc
What advancements in #CARTcell therapy have we seen in #rheumatology in 2025?
Sarah Onuora, Chief Editor of @natrevrheum.nature.com, discusses this and the other hot topics this year in our latest podcast.
Listen now 👉 buff.ly/t5vUVzy
#RheumSky #MedSky
Sarah Onuora, Chief Editor of @natrevrheum.nature.com, discusses this and the other hot topics this year in our latest podcast.
Listen now 👉 buff.ly/t5vUVzy
#RheumSky #MedSky
December 18, 2025 at 11:54 AM
What advancements in #CARTcell therapy have we seen in #rheumatology in 2025?
Sarah Onuora, Chief Editor of @natrevrheum.nature.com, discusses this and the other hot topics this year in our latest podcast.
Listen now 👉 buff.ly/t5vUVzy
#RheumSky #MedSky
Sarah Onuora, Chief Editor of @natrevrheum.nature.com, discusses this and the other hot topics this year in our latest podcast.
Listen now 👉 buff.ly/t5vUVzy
#RheumSky #MedSky
#GLP1 therapies have dominated headlines this year, but what other advancements have caught the attention of Claire Greenhill, Chief Editor of @natrevendo.nature.com?
Find out in our latest podcast 👉 buff.ly/t5vUVzy
#Diabetes #EndoSky #UPFs
Find out in our latest podcast 👉 buff.ly/t5vUVzy
#Diabetes #EndoSky #UPFs
December 17, 2025 at 9:01 AM
#GLP1 therapies have dominated headlines this year, but what other advancements have caught the attention of Claire Greenhill, Chief Editor of @natrevendo.nature.com?
Find out in our latest podcast 👉 buff.ly/t5vUVzy
#Diabetes #EndoSky #UPFs
Find out in our latest podcast 👉 buff.ly/t5vUVzy
#Diabetes #EndoSky #UPFs
What were the hot topics in #cardiology in 2025?
Dr. Gregory Lim, Chief Editor of @natrevcardiol.nature.com discusses the topics that caught his attention this year.
Listen to the full podcast here 👉 buff.ly/t5vUVzy
#CardioSky #MedSky
Dr. Gregory Lim, Chief Editor of @natrevcardiol.nature.com discusses the topics that caught his attention this year.
Listen to the full podcast here 👉 buff.ly/t5vUVzy
#CardioSky #MedSky
December 16, 2025 at 10:18 AM
What were the hot topics in #cardiology in 2025?
Dr. Gregory Lim, Chief Editor of @natrevcardiol.nature.com discusses the topics that caught his attention this year.
Listen to the full podcast here 👉 buff.ly/t5vUVzy
#CardioSky #MedSky
Dr. Gregory Lim, Chief Editor of @natrevcardiol.nature.com discusses the topics that caught his attention this year.
Listen to the full podcast here 👉 buff.ly/t5vUVzy
#CardioSky #MedSky
With #ASH2025 at an end, continue your learning in #HaemOnc
Hear directly from #AML experts about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients.
All episodes now available 👉 buff.ly/ro4GLtX
#HaemSky
Hear directly from #AML experts about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients.
All episodes now available 👉 buff.ly/ro4GLtX
#HaemSky
December 10, 2025 at 10:01 AM
With #ASH2025 at an end, continue your learning in #HaemOnc
Hear directly from #AML experts about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients.
All episodes now available 👉 buff.ly/ro4GLtX
#HaemSky
Hear directly from #AML experts about innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients.
All episodes now available 👉 buff.ly/ro4GLtX
#HaemSky
Catch up on all the latest news, guidance and expert opinions from #ASH2025, including updates in sickle cell disease, multiple myeloma, lymphoma, transplants, and more.
Access for free 👉 buff.ly/nAY050O
#Hematology #MedNews
Access for free 👉 buff.ly/nAY050O
#Hematology #MedNews
December 10, 2025 at 9:01 AM
Catch up on all the latest news, guidance and expert opinions from #ASH2025, including updates in sickle cell disease, multiple myeloma, lymphoma, transplants, and more.
Access for free 👉 buff.ly/nAY050O
#Hematology #MedNews
Access for free 👉 buff.ly/nAY050O
#Hematology #MedNews
#CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice.
We discuss how the latest research can be leveraged to optimize patient care in this free webinar 👉 buff.ly/2sspPRV
#OncSky #GastroSky
We discuss how the latest research can be leveraged to optimize patient care in this free webinar 👉 buff.ly/2sspPRV
#OncSky #GastroSky
December 8, 2025 at 7:25 PM
#CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice.
We discuss how the latest research can be leveraged to optimize patient care in this free webinar 👉 buff.ly/2sspPRV
#OncSky #GastroSky
We discuss how the latest research can be leveraged to optimize patient care in this free webinar 👉 buff.ly/2sspPRV
#OncSky #GastroSky
Prof. Edoardo Savarino takes us through the highlights of the updated UEG and ESNM #dysphagia guidelines and the difference they could make to patient outcomes.
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky #MedSky
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky #MedSky
December 3, 2025 at 1:01 PM
Prof. Edoardo Savarino takes us through the highlights of the updated UEG and ESNM #dysphagia guidelines and the difference they could make to patient outcomes.
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky #MedSky
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky #MedSky
Screening, diet, and lifestyle are the three pillars of prevention for #CRC, but how can the latest research, including that on behavioral interventions, be leveraged?
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
November 24, 2025 at 5:16 PM
Screening, diet, and lifestyle are the three pillars of prevention for #CRC, but how can the latest research, including that on behavioral interventions, be leveraged?
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
25 years since the first phase 2 trial for the first #TKI, we reflect on this key breakthrough in the treatment of #CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
November 21, 2025 at 7:25 PM
25 years since the first phase 2 trial for the first #TKI, we reflect on this key breakthrough in the treatment of #CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
Prof. Edoardo Savarino takes us through the highlights of the updated #UEG and #ESNM #dysphagia guidelines and the difference they could make to patient outcomes.
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
November 19, 2025 at 3:00 PM
Prof. Edoardo Savarino takes us through the highlights of the updated #UEG and #ESNM #dysphagia guidelines and the difference they could make to patient outcomes.
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
❗ LAST CHANCE TO REGISTER❗
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
November 17, 2025 at 9:01 AM
❗ LAST CHANCE TO REGISTER❗
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
With #AASLD2025 coming to a close, continue your learning on #ALD with our upcoming free webinar.
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
November 11, 2025 at 4:15 PM
With #AASLD2025 coming to a close, continue your learning on #ALD with our upcoming free webinar.
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer.
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
November 8, 2025 at 1:01 PM
From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer.
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
Refresh your knowledge in #oncology & #hematology:
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
November 5, 2025 at 11:54 AM
Refresh your knowledge in #oncology & #hematology:
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
From #ESMO2025 - Dr. Erica Mayer highlights the benefit of treatment with #giredestrant plus #everolimus in patients with ER-positive, HER2-negative advanced #BreastCancer who have previously received a CDK4/6 inhibitor.
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
November 3, 2025 at 11:54 AM
From #ESMO2025 - Dr. Erica Mayer highlights the benefit of treatment with #giredestrant plus #everolimus in patients with ER-positive, HER2-negative advanced #BreastCancer who have previously received a CDK4/6 inhibitor.
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
From #ESMO2025 - Prof. Jeanne Tie explains why ctDNA-guided treatment de-escalation could be considered in certain patients with #ColonCancer despite the trial not meeting its primary endpoint.
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
October 31, 2025 at 9:02 AM
From #ESMO2025 - Prof. Jeanne Tie explains why ctDNA-guided treatment de-escalation could be considered in certain patients with #ColonCancer despite the trial not meeting its primary endpoint.
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
From #UEGWeek 2025 - Yorick van de Pavert highlights the benefits of endoscopic #gastroenterostomy vs surgical for patients with malignant gastric outlet obstruction in findings from the ENDURO trial.
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
October 28, 2025 at 10:02 AM
From #UEGWeek 2025 - Yorick van de Pavert highlights the benefits of endoscopic #gastroenterostomy vs surgical for patients with malignant gastric outlet obstruction in findings from the ENDURO trial.
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
October 28, 2025 at 10:02 AM
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
Catch up on the top stories and latest innovations in #oncology from #ESMO2025 with our hub page.
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
October 22, 2025 at 10:54 AM
Catch up on the top stories and latest innovations in #oncology from #ESMO2025 with our hub page.
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
Attending #ESMO2025?
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
October 19, 2025 at 10:00 AM
Attending #ESMO2025?
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
❗ LAST CHANCE TO REGISTER❗
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
October 17, 2025 at 8:45 AM
❗ LAST CHANCE TO REGISTER❗
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd